SDMHF OTC
Sartorius Stedim Biotech S.A.
1W: +0.4%
1M: +6.5%
3M: +13.8%
YTD: -0.8%
1Y: +23.5%
3Y: -2.5%
5Y: -60.2%
$244.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Income Trends
Revenue
$3.0B
+6.7% ▲
5Y CAGR: +9.2%
Gross Profit
$1.3B
+11.4% ▲
5Y CAGR: +6.0%
Operating Income
$549M
+48.1% ▲
5Y CAGR: +3.1%
Net Income
$266M
+51.6% ▲
5Y CAGR: -4.6%
EPS (Diluted)
$2.73
+50.8% ▲
5Y CAGR: -5.6%
EBITDA
$843M
+25.8% ▲
5Y CAGR: +8.2%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.5B | $2.8B | $2.8B | $3.0B |
| YoY Growth | +51.1% | +21.0% | -20.5% | +0.2% | +6.7% |
| Cost of Revenue | $1.3B | $1.7B | $1.5B | $1.6B | $1.6B |
| Gross Profit | $1.6B | $1.8B | $1.2B | $1.2B | $1.3B |
| Gross Margin | 53.8% | 52.5% | 44.4% | 43.4% | 45.3% |
| R&D Expenses | $110M | $132M | $130M | $144M | $0 |
| SG&A Expenses | $532M | $601M | $616M | $648M | $0 |
| Operating Expenses | $670M | $752M | $771M | $836M | $796M |
| Operating Income | $865M | $995M | $450M | $371M | $549M |
| Operating Margin | 30.0% | 28.5% | 16.2% | 13.3% | 18.5% |
| Interest Expense | $10M | $19M | $117M | $164M | $153M |
| Income Before Tax | $647M | $1.1B | $401M | $219M | $373M |
| Tax Expense | $232M | $250M | $89M | $41M | $107M |
| Net Income | $414M | $876M | $310M | $175M | $266M |
| Net Margin | 14.4% | 25.1% | 11.2% | 6.3% | 9.0% |
| EPS (Diluted) | $4.50 | $9.51 | $3.36 | $1.81 | $2.73 |
| EBITDA | $799M | $1.3B | $756M | $670M | $843M |
| Shares Outstanding | 92M | 92M | 92M | 97M | 97M |